Immunology

For over 20 years, Roche has been at the forefront of immune system research. We pioneered the use of therapeutic antibodies that transformed the outlook for people with blood cancers, rheumatological disease, and areas of neurology, and we are continuing to work on treatments for allergic and autoimmune diseases. Immunology is a cornerstone of Roche’s strategy, and our innovations have not only improved people’s health but allowed them to stay active and contributing to society.

In immunology our expertise is focused where the need is greatest - addressing the debilitating effects of lung diseases like COPD (chronic obstructive pulmonary disease) and chronic inflammatory conditions of the digestive tract like IBD (inflammatory bowel disease), as well as tackling complex conditions such as atopic dermatitis, lupus and other autoimmune diseases, including those of the kidney. Looking beyond individual diseases, we target pan-immuno ‘pathways’ - the biologic and molecular signals that trigger inflammation and immune responses, which can cause an immune-mediated disease.

Working with the global immunology community, our goal is to redefine what is possible. We aren't just developing transformative medicines, we are seeking to build a new reality where a person diagnosed with an immune disease faces a very different future, one with the opportunity to live life to the full.